Evidence map›Paper›PMID 30607560›Full record

Trial reportEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2019

A new approach to vocal cord leukoplakia and evaluation of proton pump ınhibitor treatment.

Seda Sezen Goktas, Remzi Dogan, Alper Yenigun, Omer Faruk Calim, Orhan Ozturan, Selahattin Tugrul

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Genetic polymorphisms and protein levels in vocal fold leukoplakia: a systematic review.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2022
    Pooled it
  2. Vocal Folds Leukoplakia: The Efficacy of Vitamin A in the Initial Treatment.International archives of otorhinolaryngology · 2023
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Seda Sezen GoktasOtorhinolaryngology Clinic, Boyabat 75th State Hospital, Boyabat, Sinop, Turkey. sedasezengoktas@gmail.com.ORCID http://orcid.org/0000-0001-9820-958X
Remzi DoganDepartment of Otorhinolaryngology, Faculty of Medicine, Bezmialem Vakif University, Fatih, Istanbul, Turkey.
Alper YenigunDepartment of Otorhinolaryngology, Faculty of Medicine, Bezmialem Vakif University, Fatih, Istanbul, Turkey.
Omer Faruk CalimDepartment of Otorhinolaryngology, Faculty of Medicine, Bezmialem Vakif University, Fatih, Istanbul, Turkey.
Orhan OzturanDepartment of Otorhinolaryngology, Faculty of Medicine, Bezmialem Vakif University, Fatih, Istanbul, Turkey.
Selahattin TugrulDepartment of Otorhinolaryngology, Faculty of Medicine, Bezmialem Vakif University, Fatih, Istanbul, Turkey.
Bezmiâlem Vakıf Üniversitesi · TRSivas State Hospital · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOur aim is identify a new approach to vocal cord leukoplakia treatment and detect to efficiency of proton pump inhibitors. STUDY

designProspective, nonrandomized experimental clinical trial.

methodsA 'First Assessment Scale' was prepared. This scale included the lesion's and the patient's characteristics. Using this scale, 24 patients included to the study. 20 mg rabeprazole twice daily was applied to all patients. At the end of 3rd month, a 'Second Assessment Scale' was used and two groups created. In group 1, 19 patients were accepted to responsive for the therapy and received the same therapy. The group 2 was included five patients that accepted unresponsive to treatment and directed to surgery. All patients received the same treatment additionally 3 months. At the end of 6th month, the Reflux Symptom Index (RSI), the Reflux Finding Score (RFS) and the Red-Green-Blue (RGB) values evaluated and comparisons were made.

resultsThe RSI and RFS values were significantly decreased in all patients. The Red values were significantly decreased with treatment in group 1, but the Green and Blue values were not. In group 2, the RGB values were not showed the significant differences. In conclusion, seven patients (29,2%) showed complete lesion regression, 12 patients (50%) showed partial lesion regression and five patients (20,8%) showed no response to treatment.

conclusionsThe proton pump inhibitor treatment may be beneficial for the selected patients. The scales that we prepared were useful for lesion assesment.

Indexed as

AdultAgedFemaleHumansLaryngopharyngeal RefluxLaryngoscopyLeukoplakiaMaleMiddle AgedProspective StudiesProton Pump InhibitorsRabeprazoleStroboscopyVideo RecordingVocal CordsProton Pump InhibitorsRabeprazoleLaryngopharyngeal refluxLeukoplakiaPrecancerousProton pump inhibitorRabeprazoleVocal cord leukoplakia

Identifiers

PMID30607560
OpenAlexW2908422269

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.